Candel Therapeutics, Inc. (CADL)
$13.00-$0.75 (-5.45%) Today
Paul B. ManningPaul B. ManningCandel Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing off-the-shelf viral immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The immune cells induced by these viral immunotherapies are believed to target patients' specific tumor antigens, potentially improving responses in immunologically hot tumors while at the same time infiltrating the tumor microenvironment, transforming non-inflamed cold tumors with limited immune response into hot tumors. The company has established two clinical off-the-shelf viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 3 | 37,447 | $390K |
| Grant or award | 13 | 576,911 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
45 Form 4 filings on record, the earliest from Oct 3, 2024, newest first. Filing history page 2 of 2.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Estuardo Aguilar-Cordova - 10% Owner | Derivative | CADL | 100,000 | $9.00 | $900K | |
| Estuardo Aguilar-Cordova - 10% Owner | Derivative | CADL | 100,000 | $9.00 | $900K | |
| Estuardo Aguilar-Cordova - 10% Owner | Derivative | CADL | 50,000 | $8.52 | $426K | |
| Estuardo Aguilar-Cordova - 10% Owner | Derivative | CADL | 50,000 | $8.52 | $426K | |
| Estuardo Aguilar-Cordova - 10% Owner | Derivative | CADL | 50,000 | $8.82 | $441K | |
| Estuardo Aguilar-Cordova - 10% Owner | Derivative | CADL | 50,000 | $8.82 | $441K | |
| Paul B. Manning | Open-market purchase | Common Stock | 500,000 | $6.00 | $3.00M | |
| Paul B. Manning | Open-market purchase | Common Stock | 750,000 | $6.00 | $4.50M | |
| Estuardo Aguilar-Cordova - 10% Owner | Derivative | CADL | 200,000 | $8.53 | $1.71M | |
| Estuardo Aguilar-Cordova - 10% Owner | Derivative | CADL | 200,000 | $8.53 | $1.71M | |
| Estuardo Aguilar-Cordova - 10% Owner | Derivative | CADL | 200,000 | $10.04 | $2.01M | |
| Estuardo Aguilar-Cordova - 10% Owner | Derivative | CADL | 200,000 | $10.04 | $2.01M | |
| Estuardo Aguilar-Cordova - 10% Owner | Derivative | CADL | 20,000 | $4.46 | $89K | |
| Estuardo Aguilar-Cordova - 10% Owner | Derivative | CADL | 20,000 | $4.79 | $96K | |
| Estuardo Aguilar-Cordova - 10% Owner | Derivative | CADL | 20,000 | $5.23 | $105K | |
| Francesca Barone - Officer | Open-market sale | Common Stock | 22,081 | $4.56 | $101K | |
| Paul Peter Tak - Officer | Open-market sale | Common Stock | 48,847 | $4.56 | $223K | |
| Seshu Tyagarajan - Officer | Open-market sale | Common Stock | 20,392 | $4.56 | $93K | |
| William Garrett Nichols - Officer | Open-market sale | Common Stock | 13,935 | $4.56 | $63K | |
| Estuardo Aguilar-Cordova - 10% Owner | Derivative | CADL | 20,000 | $4.97 | $99K | |
| Paul Peter Tak - Officer | Option exercise | Common Stock | 12,900 | $1.55 | $20K | |
| Paul Peter Tak - Officer | Option exercise | Stock Option (Right to Buy) | 12,900 | $0.00 | - | |
| Estuardo Aguilar-Cordova - 10% Owner | Derivative | CADL | 7,500 | $5.33 | $40K | |
| Estuardo Aguilar-Cordova - 10% Owner | Derivative | CADL | 7,500 | $5.33 | $40K | |
| Estuardo Aguilar-Cordova - 10% Owner | Derivative | CADL | 7,500 | $5.19 | $39K | |
| Estuardo Aguilar-Cordova - 10% Owner | Derivative | CADL | 7,500 | $5.19 | $39K | |
| Estuardo Aguilar-Cordova - 10% Owner | Derivative | CADL | 7,500 | $4.92 | $37K | |
| Estuardo Aguilar-Cordova - 10% Owner | Derivative | CADL | 7,500 | $4.92 | $37K | |
| Estuardo Aguilar-Cordova - 10% Owner | Derivative | CADL | 6,000 | $5.38 | $32K | |
| Estuardo Aguilar-Cordova - 10% Owner | Derivative | CADL | 6,000 | $5.38 | $32K | |
| Estuardo Aguilar-Cordova - 10% Owner | Derivative | CADL | 7,500 | $5.30 | $40K | |
| Estuardo Aguilar-Cordova - 10% Owner | Derivative | CADL | 7,500 | $5.30 | $40K | |
| Estuardo Aguilar-Cordova - 10% Owner | Derivative | CADL | 7,500 | $5.27 | $40K | |
| Estuardo Aguilar-Cordova - 10% Owner | Derivative | CADL | 7,500 | $5.27 | $40K | |
| Estuardo Aguilar-Cordova - 10% Owner | Derivative | CADL | 16,427 | $5.53 | $91K | |
| Estuardo Aguilar-Cordova - 10% Owner | Derivative | CADL | 1,194 | $5.72 | $7K | |
| Estuardo Aguilar-Cordova - 10% Owner | Derivative | CADL | 1,597 | $5.80 | $9K | |
| Estuardo Aguilar-Cordova - 10% Owner | Derivative | CADL | 11,711 | $5.58 | $65K | |
| Estuardo Aguilar-Cordova - 10% Owner | Open-market sale | CADL | 15,000 | $6.05 | $91K | |
| Estuardo Aguilar-Cordova - 10% Owner | Open-market sale | CADL | 15,000 | $6.02 | $90K | |
| Estuardo Aguilar-Cordova - 10% Owner | Open-market sale | CADL | 10,412 | $6.03 | $63K | |
| Estuardo Aguilar-Cordova - 10% Owner | Open-market sale | CADL | 6,214 | $7.01 | $44K | |
| Estuardo Aguilar-Cordova - 10% Owner | Open-market sale | CADL | 26,988 | $6.92 | $187K | |
| Estuardo Aguilar-Cordova - 10% Owner | Open-market sale | CADL | 1,800 | $6.85 | $12K |
This is as far as the anonymous view goes. Create a free account for all 45 CADL filings on record.
A Form 144 is notice of an INTENDED sale, not a completed one. It often precedes the Form 4 that reports the trade actually happening.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| SESHU TYAGARAJAN | Officer | 7,000 | $82K | View on EDGAR | |
| - | - | - | - | View on EDGAR | |
| - | - | - | - | View on EDGAR |
Candel Therapeutics, Inc. (CADL) had 16 insider filings in the last 90 days, with the most recent on 2026-08-19. The full record for CADL runs to 45 Form 4 filings, the earliest from 2024-10-03. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of CADL were filed in the last 90 days. 3 purchases are on record for this company.
3 insider sales of CADL were filed in the last 90 days, totaling $390K.
This page tracks CADL Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add CADL to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
